Multimodality treatment of malignant pleural mesothelioma [version 1; referees: 2 approved]
Malignant pleural mesothelioma (MPM) is a rare disease of the pleura and is largely related to asbestos exposure.Despite recent advancements in technologies and a greater understanding of the disease, the prognosis of MPM remains poor; the median overall survival rate is about 6 to 9 months in untreated patients.The main therapeutic strategies for